Try our beta test site
54 studies found for:    "Myasthenia gravis"
Show Display Options
RSS Create an RSS feed from your search for:
"Myasthenia gravis"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Mycophenolate Mofetil in Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Drug: mycophenolate mofetil
2 Completed
Has Results
Efficacy of Methotrexate in Myasthenia Gravis
Condition: Myasthenia Gravis
Interventions: Drug: Methotrexate;   Other: Placebo
3 Active, not recruiting Tissue Repository for Studies of Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Other: No interventions
4 Active, not recruiting BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis
Condition: Myasthenia Gravis
Interventions: Drug: Rituximab;   Drug: Placebo
5 Completed FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) Patients
Condition: Myasthenia Gravis
Interventions: Drug: tacrolimus;   Drug: placebo
6 Not yet recruiting Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis.
Condition: Myasthenia Gravis
Interventions: Drug: UCB7665;   Other: Placebo
7 Completed Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis
Condition: Generalized Myasthenia Gravis
Interventions: Biological: GB-0998 (Intravenous immunoglobulin);   Procedure: Plasmapheresis
8 Terminated Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Biological: Hematopoietic Stem Cell Transplantation
9 Unknown  A Pilot Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Generalized Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Drug: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
10 Recruiting Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis
Condition: Myasthenia Gravis, Generalized
Interventions: Drug: Placebo;   Drug: CFZ533
11 Completed Intravenous Immune Globulin Treatment Compared to Placebo in Patients With Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Drug: Intravenous ImmuneGlobulin
12 Recruiting Exercise for Stable Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Other: Exercise
13 Active, not recruiting Study Comparing Two Tapering Strategies of Prednisone in Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Drug: Prednisone - Azathioprine
14 Recruiting Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Behavioral: Physical exercise programme using a rowing machine
15 Completed
Has Results
Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy
Condition: Myasthenia Gravis
Interventions: Procedure: thymectomy plus prednisone;   Drug: prednisone alone
16 Completed A Pilot Trial of Rituxan in Refractory Myasthenia Gravis
Condition: Refractory Myasthenia Gravis
Intervention: Drug: Rituximab (Rituxan)
17 Active, not recruiting Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis
Condition: Myasthenia Gravis
Interventions: Biological: CV-MG01;   Biological: Placebo
18 Terminated Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Drug: Subcutaneous immunoglobulins
19 Recruiting Trial of Orencia in Patients With Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Drug: Abatacept Injection
20 Recruiting Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Drug: HIZENTRA ®

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.